Literature DB >> 28687402

Shift within age-groups of mumps incidence, hospitalizations and severe complications in a highly vaccinated population. Spain, 1998-2014.

Noemí López-Perea1, Josefa Masa-Calles2, María de Viarce Torres de Mier3, Aurora Fernández-García4, Juan E Echevarría5, Fernando De Ory6, María Victoria Martínez de Aragón7.   

Abstract

The mumps vaccine (Jeryl-Lynn-strain) was introduced in Spain in 1981, and a vaccination policy which included a second dose was added in 1995. From 1992-1999, a Rubini-strain based vaccine was administered in many regions but later withdrawn due to lack of effectiveness. Despite high levels of vaccination coverage, epidemics have continued to appear. We characterized the three epidemic waves of mumps between 1998 and 2014, identifying major changes in susceptible populations using Poisson regression. For the period 1998-2003 (P1), the most affected group was from 1 to 4years old (y) [Incidence Rate (IR)=71.7 cases/100,000 population]; in the periods 2004-2009 (P2) and 2010-2014 (P3) IR ratio (IRR) increased among 15-24y (P2=1.46; P3=2.68) and 25-34y (P2=2.17; P3=4.05). Hospitalization rate (HR), complication rate (CR) and neurological complication rate (NR) among hospitalized subjects decreased across the epidemics, except for 25-34y which increased: HR ratio (HRR) (P2=2.18; P3=2.16), CRR (P3=2.48), NRR (P3=2.41). In Spain mumps incidence increased, while an overall decrease of hospitalizations and severe complications occurred across the epidemics. Cohorts born during periods of low vaccination coverage and those vaccinated with Rubini-strain were the most affected populations, leading to a shift in mumps cases from children to adolescents and young adults; this also reveals the waning immunity provided by the mumps vaccine. Despite not preventing all mumps cases, the vaccine appears to prevent serious forms of the disease.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Epidemiological surveillance; Immunization programs; Mumps; Severe complications; Spain; Vaccination

Mesh:

Substances:

Year:  2017        PMID: 28687402     DOI: 10.1016/j.vaccine.2017.06.075

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Influence of Ribavirin on Mumps Virus Population Diversity.

Authors:  Mirna Jurković; Anamarija Slović; Dubravko Forčić; Jelena Ivančić-Jelečki; Tanja Košutić-Gulija; Maja Jagušić
Journal:  Viruses       Date:  2021-12-17       Impact factor: 5.048

2.  Epidemiology of laboratory-confirmed mumps infections in South Africa, 2012-2017: a cross-sectional study.

Authors:  Mpho Lerato Sikhosana; Lazarus Kuonza; Nkengafac Villyen Motaze
Journal:  BMC Public Health       Date:  2020-05-12       Impact factor: 3.295

3.  SARS-CoV-2 and EBV coinfection.

Authors:  Francisco Javier García-Martínez; Ester Moreno-Artero; Sandra Jahnke
Journal:  Med Clin (Engl Ed)       Date:  2020-09-12

4.  Mumps virus outbreak related to a water pipe (narghile) shared smoking.

Authors:  Andrés Aragón; Manuel José Velasco; Ana M Gavilán; Aurora Fernández-García; Juan Carlos Sanz
Journal:  Enferm Infecc Microbiol Clin (Engl Ed)       Date:  2020-10-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.